text:
VANCOUVER — Mayor Gregor Robertson and his Vision Vancouver majority on council engaged in a "sham" public hearing to approve a massive tower on city-owned land, a lawyer for a New Yaletown community association told a B.C. Supreme Court judge Monday.
Not only had the city already negotiated a land swap deal with Brenhill Developments to permit a 36-storey condo tower on city-owned land at 508 Helmcken in return for building social housing on company land at 1099 Richards, it also failed to disclose those documents at a public hearing where the majority of attendees were opposed to the condo tower, said lawyer Nathalie Baker.
Council and staff clearly had their minds made up by the time the city held the public hearing on July 16, 2013, Baker told B.C. Supreme Court Justice Mark McEwan. The city was so bound by the terms of its contract with Brenhill that council had no room to make changes even if persuaded by public submissions, she said.
"The evidence is that members of the public had no idea that there was already a contract," she said. "It is material to the state of mind of council that they have negotiated what they think is a great deal."
"So your position is that council had its mind made up before the public hearing?" McEwan asked.
"In effect that is what I am saying … It shows a bias that they have already decided that this is a good deal," Baker said. "The whole thing is orchestrated. The public hearing was kind of a sham, a rubber stamp on a decision that is the culmination of year and a half of negotiations."
Baker is representing members of the Community Association of New Yaletown. They went to court after the Vision Vancouver majority on council disregarded its own Downtown Official Development Plan and approved Brenhill's proposal to build a massive tower that would be more than five times the density and four times higher than the maximum allowed under the plan. All three opposition members of council voted against the proposal, saying it was out of context to what the neighbourhood wanted.
This case is one of a number in which the city is being sued by community groups or associations alleging it has overstepped its authority. On Wednesday a judge will hear Concord Pacific's application to be admitted as a party in which the False Creek Residents Association is suing the city over a delayed promise to build a park near Science World.
Baker said Brenhill approached the city several years ago to see if it could swap its smaller Richards Street property across the street from the city's "larger and nicer" Helmcken parcel, which backs on to the new Emery Barnes park. Without opening the property to tender from other developers the city agreed to the swap if Brenhill would first build a 172-unit social housing complex on the Richards property. That project would replace the 84-unit Jubilee House social housing building that occupies the Helmcken address, as well as add more social housing units to the neighbourhood.
The city's land was valued at $15 million and Brenhill's at $8.4 million. Brenhill would also give the city $25 million in "community amenity contributions." Ultimately, the city agreed to a deal in which the $6.6 million difference in the land values and the $25 million in CACs would be used by Brenhill to build the social housing building. But by the time the deal was finally concluded, the size of the project had been scaled back to 152 units.
Baker said even then, there are questions about whether any of the apartments over the original 84 social housing units will be designated as "social housing," noting that the city is now considering them to be "low cost" rental housing with average monthly rates of $1,150.
In return, the city rezoned its own property to allow a floor space ratio of 17.9, far in excess of any other building in the neighbourhood. The building also would significantly overshadow Emery Barnes Park, Baker said.
McEwan questioned Baker about why she thought the city should have disclosed its documents to the public before the public hearing, noting that confidential negotiations have to start somewhere and that the city's deal was only contingent upon council approving it after the public hearing.
Baker said she didn't have any problem with council holding in camera discussions or negotiations. But they had a duty to disclose that information at the public hearing, she said. Instead, city staff, council and the developers all didn't want the public to know the details of the deal. Even when people were asking why the city was giving so much to the developer, they were not able to get any answers, she said.
"What is surprising is how glaring the omission is after you see all these documents, and how far everybody who knew about these documents went not to mention them," Baker said. "No one wanted it known that they were even in existence. There is just no mention of it ... they just didn't want the public to know about it."
The city and Brenhill have not yet presented their arguments. Brenhill owner Brent Kerr and his son Max were present for the opening day. The case is expected to be heard over four days this week.
Twitter.com: @sunciviclee
Click here to report a typo or visit vancouversun.com/typo.
Is there more to this story? We'd like to hear from you about this or any other stories you think we should know about. CLICK HERE or go to vancouversun.com/moretothestory


text:
UConn falls to Stanford for first loss
Final shot falls short in loss to Stanford
HARTFORD >> This time, the clutch shots and back-breaking 3-pointers didn't fall for Shabazz Napier. And for the first time in nearly seven years, UConn lost a non-conference home game.
Stanford overcame a 13-point deficit early in the second half and topped the 10th-ranked Huskies, 53-51, before 11,140 at the XL Center Wednesday night.
Napier, who has made huge 3-pointers and game-winning shots his specialty over the last couple of years, missed a trio of 3-pointers over the final 41 seconds. After Stanford's Josh Huestis missed a free throw with 7.7 seconds left, UConn had one last chance to win. This time, Napier eschewed the game-winning try and dished off to Omar Calhoun, who front-rimmed a shot from about 30 feet out as the final buzzer sounded.
"Somebody was on me," Napier explained. "I always have confidence in myself, no matter if I go 0-for-20, I always feel like I can make the next shot. Guys were just crowded on the right side, and it was actually 3-on-2 on that entire right side. Omar was the guy with the easiest pickings. It was a very far shot, but I definitely believe in each and every guy that they can take that shot. I thought it was going to go in, we all did. We believe in each other, but we just fell short."
It's the first loss of the season for UConn (9-1). It's also the first non-conference home loss for the Huskies since Jan. 20, 2007, a 77-73 loss to Indiana. And Husky fans certainly don't want anything to remind them of that 2007 season.
This year's UConn team is much better than that young squad that didn't even get an NIT bid, of course. But Wednesday's loss is a tough one for the Huskies, who can't afford to lose too many games against major-conference foes. They head out to Seattle Thursday morning for a bout with Washington on Sunday afternoon.
"This is going to be a good resume win for (Stanford)," UConn coach Kevin Ollie noted. "This is a bad loss for us, because this is like a road game, because we've got a long trip out to Washington. We've got to take care of business, and we didn't take care of business."
Through no real fault of its own, UConn's non-conference schedule — which appeared so daunting before the season began — suddenly doesn't seem as impressive.
The Huskies, relegated to the American Athletic Conference after the Big East's breakup, have two ACC teams (Boston College, Maryland), two Pac-12 squads (Stanford, Washington), a Big Ten (Indiana) and an SEC team (Florida) on its schedule.
UConn had won its first four bouts with major-conference foes until Wednesday night. Problem is, even those wins – three of them by a single point, another by two – don't look quite like the resume-builders they might have appeared to a short month or so ago.
Boston College is 4-7 and going nowhere. Maryland (7-4) and Indiana (8-3) have hardly looked impressive and may have long roads ahead for NCAA tournament berths. The win over No. 16 Florida was no doubt a big one, though we can nitpick: the Gators were without a pair of stud freshmen, Kasey Hill (injury) and Chris Walker (eligibility issues), and, for the final two minutes, without their terrific point guard, Chris Wilbekin, who sprained his ankle and had to leave the game.
That it took a lucky bounce and a Napier buzzer-beater to beat a depleted Gator squad, at home, might not engender great confidence in this team, no matter how exciting a win it was.
At least Napier bailed them out of that one. He couldn't do so on Wednesday.
"I wasn't able to knock down the shot, none of us were able to knock down the shots," he said. "I'm kind of upset with the way I played in the second half, the way I ran my team in the second half. I really felt like this was going to be a good win for us, and I didn't come through."
Napier missed a trey attempt with 41 seconds left, another eight seconds later and, after Huestis hit one of two free throws, misfired on a fallaway with eight seconds left. Ollie would have preferred Napier try to take the ball to the hole, rather than rely on contested 3's.
"With Shabazz, you live with that, because he's put this team on his back a lot of times," Ollie said. "But, he could have taken it to the basket a couple of times. He settled for the long 3-ball, and that wasn't going in tonight. So, you have to make adjustments as a player and as a coach. We just didn't make those game-winning adjustments."
For a while, it appeared UConn was on its way to perhaps its most impressive win of the season. The Huskies led 38-28 at the break and led by 13 a little over three minutes into the latter half. But the Cardinal extended its zone defense, and suddenly the Huskies looked at it as if it was rocket science.
UConn shot a woeful 16 percent (5-for-31) in the second half. It misfired on all 12 of its 3-pointers. Stanford didn't exactly scorch the nets itself, but enough to pull out the victory.
UConn's RPI, which was No. 2 in the land a few weeks ago, was down to No. 13 entering last night's action. Still a very impressive number, no doubt, but one the Huskies won't have a great chance at improving a whole lot after the New Year. Washington (6-4) isn't much, though it is a road game, and the only ranked conference foes the Huskies will face are No. 6 Louisville and No. 15 Memphis (twice each). Somewhat surprisingly, Harvard – a team that's getting some AP Top 25 votes — will be one of UConn's more impressive opponents going forward.

subset: commoncrawl


text:
Nokia will ship it latest clamshell handset next quarter, pitching the mid-range product at European buyers.
The Nokia 6125 provides quad-band GSM (850/900/1800/1900MHz) network access with EDGE for worldwide coverage, and there's Bluetooth 2.0 on board for data synchronisation and headset support - including wireless stereo headphones. The phone has a 1.3-megapixel camera with 8x digital zoom feeding the main 1.8in, 128 x 160, 262,000-colour screen. The back-up display is a 1.4in, 96 x 65, 65,5360-colour job.
The 6125 has its own Macromedia Flash Player, enabling users to enjoy rich content on their phone, and there's a digital music player app capable of handling MP3, MP4, AAC, AAC+, eAAC+ and WMA files, Nokia said. If that's insufficient for your audio needs, there's an FM radio built in too.
The phone measures 9 x 4.6 x 2.4cm and weighs 98g. Inside sits 11MB of memory, expandable using the phone's MicroSD card slot. The battery is a 820mAh unit which Nokia claimed will provide 2-5 hours' talk time and 160-280 hours' on standby.
The 6125 ships in Q2 for around €230 (£157/$280), excluding taxes and subsidies. ®


text:
- (-) Remove Special Topics Courses filter Special Topics Courses
- (-) Remove Governance filter Governance
- (-) Remove Centers and Programs filter Centers and Programs
- (-) Remove Tools filter Tools
- (-) Remove Special Topic Courses filter Special Topic Courses
- People (1620) Apply People filter
- MBL Courses (777) Apply MBL Courses filter
- Local Area (235) Apply Local Area filter
- Campus (135) Apply Campus filter
- Publications (75) Apply Publications filter
- Community Events (12) Apply Community Events filter
- Organisms (9) Apply Organisms filter
- Lectures (4) Apply Lectures filter
- Professional Meetings (4) Apply Professional Meetings filter
- MBL course (3) Apply MBL course filter
- Education Outreach (2) Apply Education Outreach filter
- Library (2) Apply Library filter
- Educational Outreach (1) Apply Educational Outreach filter
- Places (1) Apply Places filter
Massachusetts Certificate of Incorporation for the Marine Biological Laboratory
Purpose "to establish and maintain a laboratory or station for scientific study and investigation, and a school for instruction in biology and natural history"Created: 1888-03-20
Certificate of Affiliation, Marine Biological Laboratory and University of Chicago
Certificate of affiliation between the Marine Biological Laboratory and the University of ChicagoCreated: 6/10/13
Proposal to establish a marine biological laboratory
Includes solicitation of subscriptionsCreated: 1887-04-06
MBL Agreement of Association
Purpose "to establish and maintain a laboratory or station for scientific study and investigation, and a school for instruction in biology and natural history"Created: 1888-02-27
Net Work. Image #2
Man working on large mesh net.Created: 1951
Net Work. Image #1
Man working on hand netCreated: 1951
Apparatus. Image #4
One man with apparatus in hand.Created: 1951
Apparatus. Image #1
One man looking at an item on a shelf. Other shelves filled with miscellaneous partsCreated: 1951
Still construction
Two men putting together or repairing a large stillCreated: 1951
Barron's Warburg.
Woman taking notes in front of large circular Warburg apparatus.Created: 1951
Man removing samples from scientific oven.Created: 1951
Man operating distillation apparatus.Created: 1951
X-ray room, Mr. Hyde. Image #6
Man operating dials on x-ray machine.Created: 1951
X-ray room, Mr. Hyde. Image #5
Man looking up at metal balls of x-ray machine.Created: 1951
X-ray room, Mr. Hyde. Image #4
Lab image reflected in metal balls. Small viewCreated: 1951
X-ray room, Mr. Hyde. Image #4
Lab image reflected in metal balls. Small viewCreated: 1951
X-ray room, Mr. Hyde. Image #3
Man bending over x-ray machine.Created: 1951
X-ray room, Mr. Hyde. Image #2
Man using clamps to move test tubeCreated: 1951
X-ray room, Mr. Hyde. Image #1
Man operating x-ray machinery.Created: 1951
Methods for obtaining and handling marine eggs and embryos
Manual describing methods for handling embryological materials available at Woods Hole, MassachusettsCreated: 1957
Key to photo of the Parasitology course photo in 1987.
PARASITOLOGY_1987-1.jpeg: Key to photo of the Parasitology course photo in 1987.Created: 1987
Traced outline of 31 people posing the Microbiology course group photo in 1983
MICROBIOLOGY_1983-1.jpeg: Traced outline of 31 people posing the Microbiology course group photo in 1983. Each person has a name and number written upon them. "1. ?, 2, Ken Noll, 3. David White, 4. Chuck Robertson, 5. Pete Greenberg, 6. Dale Sutherland, 7. Brian Wrenn, 8. Bill Sutton, 9. George Skladany, 10. Brad Marten, 11. Trish Hartzell, 12. Tom Kieft, 13. Jim Romesser, 14. Ed Ruby, 15. Dick Castenholz, 16. Jean Poindexter, 17. Nick Santoro, 18. Karin Malmcrono-Friberg, 19. Alan Decho, 20. Lisa Muehlstein, 21. Asa Jouper, 22. Alex Keynan, 23. Joe Boyer, 24. Jessica Rich, 25.Created: 1983
Key to people featured in class photo for the microbiology course in 1985
MICROBIOLOGY 1985-1.jpeg: Key to people featured in class photo for the microbiology course in 1985 "Microbiology 1985 1st Row L to R 1. Carol Summers, 2. Mark Smith, 3. Alejandro Marineclarena 4. Pierre Rouviere 5. Rene Schwarzenback, 6. Waltraud Dilling, 7. John Coutinho, 8. Jonathan Trent. 2nd Row L to R 1. Alicia Stanton, 2. Jane Warshaw, 3. Ken Noll, 4. Heidi Kaplan, 5. Tom Booik, 6. Alan Lewitus, 7. Bernhard Schink, 8. Ralph Wolfe. 3rd Row L to R 1. Cindy Bryden, 2. Mercedes Pascual Spada, 3. Kendall Gray, 4. Wendy O'Brien, 5. Cami Harwood, 6. Tuck Leadbetter, 7.Created: 1985
Key to people featured in the Marine Ecology 1988 class photo.
MARINEECOLOGY_1988-1.jpeg: Key to people featured in the class photo. "Marine Ecology 1988 Front Row Left to Right: Sabine Dittmann, Eric Keller, Carola Schmager, Dagmar Lackschewitz, Saxon Gibson, Conxita Avila, Beatrik Hoecker, susan Kane, Tori Hatch, Tod Gillmore, Wesley Toller, Rosana Rocha, Juli Berwald, Robert Rowan. Back Row left to right: Fred Dobbs, Bob Whitlach, Margo Crabtree, Ken Foreman, Rick Osman, Donals Morrisey, James Pinckney, cheryl Ondeka, Marshall Pregnall, Maribel Pregnall, Chris Maier, Aaron Corkum, Mark Willcox, Roberto SandulliCreated: 1988
Key to class photo of the History of Biology course in 1987.
HISTBIOLOGY_1987-1.jpeg: Handwritten list of people featured in the class photo for the History of Biology course in 1987. "Left to right. Front row: Wayne Walley Willis, Thomas Gariepy, Anne Fausto-Sterling, Susan Lewin, James Ascuitto, Richard Burian, Nadine Weidman, Robert Richardson, Sara Miles, Viviane De Jonghe-Murphy, sitting (left to right) John Opitz, Bill Wimsatt, John Shaver, 2nd row: Berton Leach, Marc Swetlitz, Marlene Karustis, Joyce Cadwallader, Anne Mylott, Jane Maienschein, Heidi Howard, Carol Hogan, Scott Bilbert, Sherrie Lyons, Robert Olby, Surindar Paracer.Created: 1987


text:
The Life Sciences Report: George, we spoke almost exactly six months ago. You said that biotech stocks had a breeze to their backs. I've just looked at an unweighted index of your coverage list: It is up 30% since that time, and up 67% from 12 months ago. You have done well. Investors are always in a bottom-up market to a great degree, but does this market have long and strong legs from here, with a continued breeze?
George Zavoico: From a fundamental standpoint, in terms of science and clinical trial milestones, yes. The biotech market has long and strong legs from here. Quite a few companies are projecting announcement of top-line results of proof-of-concept or phase 3 trials before year-end, either by press release and/or at clinical conferences. The summer is relatively quiet with regard to clinical conferences, so the fact that valuations of many companies held up or increased during the past two or three months is a good sign. However, unrelated national and global geopolitical events that negatively impact market and economic perceptions can quickly reverse any such positive trend and upset the fundamental value of biotech companies.
" One can't look at a biotech and just look at the science; many other factors come into play that may determine how successful a company may be in the long run."
Having said that, before the year ends I am expecting key clinical trial results from several companies. I think Agenus Inc.'s (AGEN:NASDAQ) partner, GlaxoSmithKline (GSK:NYSE), could report results from one or more of its phase 3 trials of Agenus' novel QS-21 Stimulon vaccine adjuvant, the first for malaria, followed by one or two cancer vaccines next year. Peregrine Pharmaceuticals Inc. (PPHM:NASDAQ) is likely to report overall survival results from its front-line open-label phase 2b trial of bavituximab in combination with carboplatin and paclitaxel in non-small cell lung cancer. ArQule Inc. (ARQL:NASDAQ) has guided to reporting interim results from its pivotal phase 3 trial, called MARQUEE and conducted in partnership with Daiichi Sankyo Co. (DSKYL:OTCPK), of tivantinib + erlotinib (Tarceva, produced by Roche Holding AG [RHHBY:OTCQX]), in non-squamous non-small cell lung cancer. Keryx Biopharmaceuticals Inc. (KERX:NASDAQ) expects to announce results of its 58-week safety and efficacy phase 3 trial of Zerenex for the treatment of hyperphosphatemia (elevated serum phosphate levels in end-stage renal disease). Acadia Pharmaceuticals Inc. (ACAD:NASDAQ) has guided to reporting top-line results from its phase 3 trial of pimavanserin in the treatment of Parkinson's disease psychosis, and Threshold Pharmaceuticals (THLD:NASDAQ) is likely to report overall survival results from its phase 2 trial of TH-302 + gemcitabine in pancreatic cancer. It is also worth mentioning that the FDA scheduled an advisory committee meeting to discuss Dynavax Technologies Corp.'s (DVAX:NASDAQ) biologics license application (BLA) for Heplisav, its hepatitis B vaccine, in November, ahead of a February Prescription Drug User Fee Act (PDUFA) date.
With important milestones like these, which could add substantial value with positive results, you can see that the breeze, as you say, is continuing to back the biotech sector. Note that these examples are only a sampling from several companies the life sciences team here at MLV & Co. covers.
TLSR: I've had some natural resource investors tell me recently that they are moving into life sciences, particularly into biotech. When do you begin to see these kinds of moves as contrarian indicators?
GZ: I suspect investors are broadening their exposure into the sector because biotech company valuations are not dependent on fluctuations in commodity prices. Moreover, as you point out, not only have many biotech companies under coverage at MLV & Co. done rather well in over the past six months and one year, the two key biotech indices have also performed quite well, with the NYSE.Arca Biotechnology Index (BTK) and NASDAQ Biotechnology Index (NBI) up 26% and 45% from a year ago, respectively. Investors tend to move to better performing sectors, which could explain the renewed interest in biotech.
You also asked when these moves become contrarian. This is more difficult to judge, but the answer lies in looking at the stock price relative to valuations, according to our models. We may see recommendations moving from buys to holds based on overbuying and momentum, and not necessarily on company fundamentals. However, poor clinical trial results obviously change the fundamentals and are valid reasons for a downgrade.
TLSR: I meant to ask you, in our previous interview, about the process of your move from molecular translational research at big pharma and small biotech companies to a different kind of research, that being on the sellside at a boutique investment bank. You used to be on the team, but now you're the referee. What was the most difficult mental transition you had to make?
GZ: The transition was not that quick, as I formed and ran my own biotech consultancy and medical writing company for a few years in between. Since I was pretty much in the laboratory or managing a lab before going into consulting, this step exposed me to aspects of the business that I had not experienced in the labnotably clinical and regulatory affairs, financial due diligence and company management issues. One can't look at a biotech and just look at the science; many other factors come into play that may determine how successful a company may be in the long run.
TLSR: Last time we spoke you said you had a special interest in molecular diagnostics. Aren't these susceptible to commoditization? A competitor can maneuver around another company's IP and devalue the originator's idea. Of course, that can be done with drugs too, but not in 1836 months, which is plausible for developing a biomarker. How do you perform due diligence around this possibility?
GZ: There are two aspects to molecular diagnostics. You can get a snapshot of a patient, just as you would with typical lab tests, with regard to electrolytes, oxygen saturation, blood cell counts etc. But in this case you are measuring the presence or absence of a particular enzyme or mutation. These kinds of tests are more likely to become "commoditized," as you say. They add value by helping to more accurately evaluate a patient's prognosis.
" Investors tend to move to better performing sectors, which could explain the renewed interest in biotech."
The other type of molecular diagnostic is predictivedetermining the likelihood that a particular drug or treatment regimen will actually provide clinical benefit. Typically, these diagnostics don't measure a single parameter, but a gene expression profile. Moreover, more rigorous clinical trials are needed to show the correlation between treatment choice and benefit. These types of tests are more difficult to commoditize, especially since the ability of a company to conduct these trials, publish the results to validate the correlation, convince physicians and patients to use the product, and obtain reimbursement from third-party payers is not a trivial matter. We think these types of diagnostics will be much more difficult to commoditize. Genomic Health Inc. (GHDX:NASDAQ) has taken this approach and no real competitors have emerged.
TLSR: Because of your training as a working research scientist, I wanted to get your take on why more biomarkers/diagnostics are not developed as targets for inhibitors or agonists (chemical triggers for stimulating cellular responses). Are they generally too far downstream of effective targets? Why don't we see small diagnostics companies licensing out targets and ligands related to reagents?
GZ: I think you've largely answered your own question. Biomarkers are the relatively stable products of one or more upstream reactions, one of which would be the drug target. Moreover, diagnostics companies typically don't have the research and development expertise or infrastructure to support validation and patenting of potential targets, which leads to ownership and the capability of out-licensing.
TLSR: George, Resverlogix Corp. (RVX:TSX) is performing well, but is the cholesterol-modulating space getting crowded?
GZ: There is a very large potential market in this space, despite the continuing widespread use of statins, which explains the high level of interest. Even with improved control over cholesterol levels with statins, many people still suffer or die from acute coronary events or strokes. Resverlogix has a product with a unique mechanism of action that makes it stand out, in my view. And with notable failures in the high density lipoprotein (HDL)-raising space, RVX-208 is beginning to attract attention, especially with recent news showing that its phase 2b SUSTAIN trial of RVX-208 significantly increased levels of HDL-C and Apo A-1.
TLSR: Because of all the companies and products squeezing in to this space, will the hurdles for RVX-208 be very high?
GZ: The hurdles are high primarily because trials of drugs for atherosclerosis must be large to account for patient variation and event rates. While reductions in major adverse cardiac events (MACEs) are typically the key primary endpoint the FDA likes to see, others can serve as surrogate endpoints and this translates into smaller, more cost-effective, signal-seeking trials. Resverlogix chose plaque regression, measured by intravascular ultrasound (IVUS), as its primary endpoint in another signal-seeking trial, called ASSURE. This endpoint could also serve to validate its mechanism of action. We think this validated endpoint would be evident before many MACE events would occur.
TLSR: Does the fact that RVX-208 is an agonist rather than an inhibitor make it more appealing? Could there be fewer off-target effects?
GZ: It's actually a bit more complicated than that. RVX-208 is an inhibitor of a bromodomain and extra-terminal, or BET, protein involved in the transcription of Apo A-1, an apolipoprotein component of HDL that transports cholesterol out of plaques. Thus, while it's an inhibitor, it increases circulating levels of Apo A-1, hence some confusion about it being an agonist or inhibitor. In my mind, it doesn't matter if it's an agonist or inhibitor, as long as it works to reduce atherosclerotic plaque burden. We should learn whether RVX-208 does this when top-line results from ASSURE are reported, most likely before the middle of next year.
TLSR: Moving on to a different issue, development of Aastrom Biosciences Inc.'s (ASTM:NASDAQ) ixmyelocel-T for critical limb ischemia (CLI) feels like it's taking forever. Is the primary endpoint limb sparing at 12 months?
GZ: Yes. To use the clinical term, the endpoint is amputation-free survival. Once there's an amputation, the quality of life of a patient diminishes substantially, while the cost and effort needed to provide sufficient care rises. The key to the design of this trial, called REVIVE-CLI, is targeting patients who are most likely to experience an event within the one-year time frame of the trial. It would be counterproductive and reduce the likelihood of success to enroll patients not likely to experience an amputation event within a year, or to enroll patients who are so far along in their disease process that they would require an amputation regardless of therapy. Aastrom spent a lot of time in determining patient inclusion and exclusion criteria, which identifies patients at risk of an amputation event within a year and, therefore, would be most likely to benefit from ixmyelocel-T therapy. The screening protocol takes time and we expect that a number of patients initially deemed eligible by their treating physicians will not meet the criteria as adjudicated by the central review committee of the trial.
TLSR: Is the company not able to move this proposed therapy into patients at an earlier disease stage? Or, must it be tested in patients who are sure to lose the limb unless they receive a dramatic therapy?
GZ: They could redefine the criteria, but it would be a much larger, longer, and therefore far more expensive trial. REVIVE-CLI is enrolling patients with no other options for treatment. By addressing an unmet clinical need, we think it is the fastest path to market.
TLSR: With regard to Threshold Pharmaceuticals, given the unmet need in pancreatic cancer and the exciting data from the phase 2b study in February, I wonder if there is any possibility of an accelerated approval of TH-302?
GZ: Definitely, but for an upcoming phase 3 trial. The phase 2b trial by itself was not designed as a pivotal trial since overall survival was a secondary endpoint. I envision a phase 3 trial of similar design, and most likely involving one of the two TH-302 doses evaluated in the phase 2b. If you've got success in phase 2b, typically there is no reason to make big changes to the trial design.
TLSR: Do we know yet if TH-302 has demonstrated any benefit in overall survival? Could it be approved based only on progression-free survival (PFS), assuming that quality of life is improved?
GZ: We are still awaiting median overall survival (mOS) results and, as I mentioned before, those are expected before year-end. Conservatively, a phase 3 trial will be required. Recall that the primary endpoint of this trial was median PFS, so typical of phase 2b trials, this one was not powered to show a statistically significant difference in mOS. But as you point out, in indications with clear unmet clinical needs, where a prolongation of survival would make a big difference, exceptions can be made. I suspect if the mOS results show a statistically significant difference between the two arms, as we hope they will, Threshold will request a meeting with the U.S. Food and Drug Administration (FDA) to determine its options, one of which could be submission of a new drug application based on the phase 2b trial.
TLSR: I'd like to ask you to discuss Prana Biotechnology Ltd. (PBT:ASX), an Australian company targeting very difficult indications, including Alzheimer's disease and other neurodegenerative diseases. Have they been chasing a wild goose in targeting beta amyloid?
GZ: I would argue that specifically targeting beta amyloid, but not how it gets there in the first place, is the wild goose chase. Recently we have had two high-profile phase 3 failures in Alzheimer's disease: Pfizer Inc. (PFE:NYSE) and Johnson & Johnson's (JNJ:NYSE) bapineuzumab and Eli Lilly and Co.'s (LLY:NYSE) solanezumab did not meet their primary endpoints. Both are antibodies designed to reduce the beta amyloid plaque burden without addressing the underlying pathology that got the plaques there in the first place.
"The biotech market has long and strong legs."
In the past several years a new hypothesis has emerged as to how the beta amyloid plaques begin to form and, perhaps even more important, how another neuronal protein, tau, is hyperphosphorylated, enabling it to form neurofibrillary tangles. The key event is age-related dysfunction in the control of transition metal levels in neuronal synapses. Metals like zinc, copper and iron have a number of important biologic functions, most notably in the function of numerous enzymes and receptors. Zinc, in particular, binds to beta amyloid, leading to its aggregation and, ultimately, plaque formation. In preclinical studies, Prana's lead drug candidate, PBT2, has been shown to redistribute zinc and other transition metals, preventing beta amyloid aggregation and even inducing its disaggregation. Sequestration of zinc in beta amyloid plaques reduces zinc levels inside the neuron, which can lead to its hyperphosphorylation. The metals hypothesis appears to unify the pathology underlying both amyloid plaque and neurofibrillary tangle formation, which makes this approach so compelling, in my mind.
TLSR: How many companies are approaching central nervous system diseases from the metallic equilibrium perspective? Is Prana alone in this?
GZ: I don't know of any other company as far along in this approach as Prana. They have two phase 2 trials ongoing, one in Alzheimer's disease, the other in Huntington's disease. Top-line results are expected by the end of next year.
TLSR: It would be amazing if both Alzheimer's and Parkinson's had a common etiology. Could one agent actually manage ionic equilibrium in neurons?
GZ: Yes. Parkinson's, as well as Huntington's disease, are characterized by misfolded proteins that aggregate, ultimately leading to nerve cell injury and death. In Parkinson's, it is a protein called alpha-synuclein, and in Huntington's, it is a different protein called Huntingtin protein. Notably, this pathologic protein aggregation appears to be driven by the abnormal distribution of the metals. PBT2 is the first "metal-protein attenuation compound," as Prana calls it, to enter the clinic for these neurodegenerative disease indications. If the metals hypothesis holds up, then it is possible that one agent could restore metal ion homeostasis in neurons.
TLSR: I would like you to discuss BioCryst Pharmaceuticals Inc. (BCRX:NASDAQ). It's hard to look at preclinical compounds as having value, but BCX5191 for hepatitis C (HCV) is starting to look like a smart development project. Given the recent issues with nucleotides, and with less pharmacokinetic activity required for drug activity, do you think BCX5191, a nucleoside, will be monetized soon? Does this look like an asset someone would pay for?
GZ: The fact that BCX5191 is a nucleoside could be an important advantage. It is not a prodrug (an inactive drug that is activated in the body by normal metabolic processes), as are the nucleotides, and it has shown high potency, as well as no notable toxicity, in preclinical studies. BioCryst has guided to filing an investigational new drug application and starting a phase 1 trial before the end of the year. I agree that this looks like a smart development project, as it is a new approach in this space. But as far as monetizing this asset, I think it is too early right now. There's no clinical data, so its value is low. In my view, BioCryst would be giving it away if they out-licensed the therapy now. Its value could increase substantially with positive phase 1 or 2 results.
I should add that the key value driver for BioCryst right now is its gout drug, ulodesine. A 52-week study demonstrated that ulodesine, in combination with the current standard of care, allopurinol, was safe and more effective than allopurinol alone. The proportion of patients who reached the therapeutic goal of achieving and maintaining serum uric acid levels below the target level was double with the combination therapy, as opposed to treatment with allopurinol alone. We expect BioCryst to announce a partnership deal for this asset long before it does so with BCX5191.
TLSR: Lastly, Spectrum Pharmaceuticals Inc. (SPPI:NASDAQ) has been in the news lately with its acquisition of Allos Therapeutics Inc. (ALTH:NASDAQ). What is your view on that? Is it a value driver?
GZ: I believe it is. In 2011, Allos reported $50.5 million (M) in net sales of its only marketed product, Folotyn (pralatrexate), which is indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Net Folotyn sales have been about $20.7M so far this year. In 2012, Spectrum guided to pro forma revenue of $300M, about $4045M more than we projected for the company. In our view, by acquiring Allos, Spectrum purchased future revenue without any taking on any substantial burden in new operating expenses. We think the company can integrate Folotyn sales and marketing within its existing infrastructure for Fusilev (levoleucovorin) and Zevalin (ibritumomab tiuxetan) at minimal cost.
Evidence shows Folotyn is more effective than methotrexate, a generic analog. Nevertheless, it is associated with a high incidence of mucositis. One of the intriguing aspects of this acquisition is figuring out how to use Folotyn more effectively, since an approved indication for Fusilev, one of Spectrum's other marketed products, is to diminish methrotrexate toxicity. I think we'll see a number of new trials exploring combinations of Folotyn and Fusilev to determine if there are any synergies in improving efficacy and safety. If so, then both drugs should see increased market penetration. If not, Spectrum should be able to grow the Folotyn PTCL market and collect north of $50M in revenue every year.
TLSR: Thank you for sharing your insights.
GZ: Thank you, my pleasure.
George B. Zavoico, Ph.D., has more than seven years of experience as a life sciences analyst writing research on publicly traded equities. Prior to joining MLV & Co, he worked at Westport Capital Markets LLC and Cantor Fitzgerald in their research departments. He received The Financial Times/Starmine Award two years in a row for being among the top-ranked earnings estimators in the biotechnology sector. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical and molecular diagnostics companies engaged in discovering, developing and marketing drugs and value-added diagnostics for the diagnosis and treatment of cancer and cardiovascular, inflammatory/immune and central nervous system diseases and disorders. Prior to working as an analyst, Zavoico established his own consulting company, serving the biotech and pharmaceutical industries by providing competitive intelligence and marketing research, due diligence services and guidance in regulatory affairs. He also wrote extensively on healthcare and the biotech and pharmaceutical industries for periodicals targeting the general public and industry executives. Zavoico began his career as a senior research scientist at Bristol-Myers Squibb Co., moving on to management positions at Alexion Pharmaceuticals Inc. and T Cell Sciences Inc. (now Celldex Therapeutics Inc.). He has a bachelor's degree in biology from St. Lawrence University and doctorate in physiology from the University of Virginia.
Want to read more exclusive Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Exclusive Interviews page.
1) George S. Mack conducted this interview. He personally and/or his family own shares of the following companies mentioned in this interview: None.
2) The following companies mentioned in the interview are sponsors of The Life Sciences Report: Resverlogix Corp. Johnson & Johnson is not affiliated with Streetwise Reports. Streetwise Reports does not accept stock in exchange for services. Interviews are edited for clarity.
3) George Zavoico: I personally and/or my family own shares of the following companies mentioned in this interview: None. I personally and/or my family am paid by the following companies mentioned in this interview: None. I was not paid by Streetwise Reports for participating in this interview.
4) Disclosures for MLV & Co. can be found here.


text:
Design Strategies of Successful Communities
IN TERMS OF THEIR SOCIAL DYNAMICS, physical and virtual communities are much the same. Both involve developing a web of relationships among people who have something meaningful in common, such as a beloved hobby, a life-altering illness, a political cause, or a professional relationship. In one sense, a Web community is simply a community that happens to exist online, rather than in the physical world.
I've been building online communities for ten years. Again and again, regardless of technology, I've found myself bumping up against the same basic issues in my work--issues like persistent identity, newcomer confusion, etiquette standards, leadership roles, and group dynamics.
About five years ago, I summarized these issues into a set of design guidelines that I use in my consulting practice. Through conversations with community leaders, both on and off the Web, I learned that all communities are ultimately based on timeless social dynamics that transcend the medium of connection. In other words, people are people, even in cyberspace.


text:
DWTS Season 10 – Rumor Roundup Part II
Okay, where was I? My first post from yesterday on this topic ended with Lou Ferrigno, so I'll pick it up from there. As I mentioned yesterday, the rumors about who will be on DWTS often start a couple seasons before they actually appear on the show, so we decided to list those rumors from the last several months once again – just in case. 🙂
But first we have a NEW case of a celeb wanting to be on the show and telling everyone she wants to be on the show, at least according to OK! Magazine:
Former Boy Meets World star and current The Dish host Danielle Fishel aspires to be on Dancing With The Stars in 2010.
"I've told them really straight forwardly that I really want to do the show, and unfortunately they've got thousands of other celebrities that feel the exact same way," she tells me. "There are so many people who want to do that show because it's a real classy show, especially for reality TV. I told them I'm interested, they know I'm interested, and hopefully one day they'll think I'd be a good fit for the show. "
Her dream partner is Maksim.
"He is the biggest, manliest dancer they have on that show, and I think for me to have a male dance partner, I would want someone that I felt very feminine next to. I think he's the manliest dancer on the show."
Okay, on with the roundup:
Leslie Jordan – he's that cute little comedian with the southern accent. As I said originally, this was likely wishful thinking on Leslie's part – plus he might even be shorter than Chelsie. 🙂 This is one of the rumors that I desperately wanted to be true.
Heh, I just realized that I called both Debi Mazar AND Aaron Carter in July. Dang, that was early – which means that anything I hear NOW could also be true.
Greg Louganis – This was according to Celebuzz and I was so-so on it at the time, in terms of likelihood, but I think Greg's appearance on last season in that Olympian segment solidified his chances to be on either this season or in the fall. I'm gonna go out on a limb and say Greg in 2010 – one season or the other. 🙂
Jordan Knight – this one was twitter based, but then that's how Debi Mazar and Aaron Carter started out. Who's to say Jordan wasn't on the list, but Aaron got picked instead. Jordan could be this seasons Aaron.
Dean McDermott – around the same time that Jordan was being rumored, there was a ton of talk about Dean – often by his wife. I believe they did talk to him so maybe we'll see him this year.
Beth Horn – this one was more of a campaign to get her on the show than any real rumor she would indeed be on. I don't know if campaigns have any impact whatsoever, and I never saw anything other than campaigning to indicate she might be on the show. That casts a good deal of doubt on the odds. We'll see!!
LOL – I found the Kelly Osbourne thing and called a few things correctly. I said Mark or Derek as her partner and she was rumored to be originally partnered with Mark before she told producers that she wanted someone she could push around – so she was subsequently moved to Louis. Good call, Kelly. 🙂
Shari Sheppard, Alicia Sacramone, Andrew Firestone and Aubry O'Day were on a list of rumored cast members that I had not seen anywhere else other than the single blog – and that list included some HIGHLY implausible people, so I'm thinking it was more of a wish list than actual, potential celebs. I could be wrong.
Jeremy Roenick, Tori Spelling and Lynda Carter – these were either said jokingly or were strictly twitter related. I think Lynda is the only plausible one at this point.
Let's not forget the ubiquitous Paula Abdul rumor. That one was so prevalent before last season that I'm not even going to provide a link. Heck, Conrad Greene basically admitted that he asked her.
LaToya Jackson – it was widely reported that the only reason she wasn't on last season was because of Michael's death (Jermaine was also occassionally included in this rumor). LOTS of people are pretty convinced that she will be on this coming season and that she'll demand Derek as a partner. At the point this becomes true, I won't know whether to jump off a cliff or be intrigued by the possibility.
Brandy and her brother – could have been mass confusion or a mix up. Who knows.
Dan Cortese – Dan was told – and proclaimed to the world on Twitter – that he was in the running for the last guy spot last season. That makes him a possibility for this season, in my book. I'm cool with this because he's hot. 😉
Jennifer Grey – Jennifer was rumored for last season as I mentioned in a post about Joanna Krupa (and correctly called her partner as Derek), and she is also being rumored for this season. I think she's likely to show up sooner or later.
That should bring us pretty much up to the "current" rumors as I've been posting then since Season 9 ended. Once we get farther along, I'll make a complete list of previous rumors and current rumors. I do like lists, you know. 🙂


text:
I have a list in which there are few items, So when i click on any item, it will go to the next activity and there is a rating bar, Now my question is how can i store the rating bar value for example "5" in mysql php database from android.
Please help.
I did not find the right solution from the internet.


text:
Markey holds firm on comments comparing campaign finance ruling to Dred Scott
Representative Edward Markey is refusing to back down from comments he made this week that seemed to compare the US Supreme Court's decision on campaign finance law to the high court's 19th-century Dred Scott decision, which upheld slavery.
On Tuesday, at a campaign rally in Pittsfield, the Democrat said that if he is elected to the Senate he would fight for a constitutional amendment to overturn Citizens United, the 2010 case that eliminated limits on campaign donations.
"The whole idea that the Koch brothers, Karl Rove can say we're coming to Massachusetts, that we're coming to any state in the union with unlimited amounts of undisclosed money is a pollution, that must be changed,'' Markey said, according to a video of the event provided by the National Republican Senatorial Committee.
"The constitution must be amended. The Dred Scott decision had to be repealed, we have to repeal Citizens United,'' he added.
Markey made the comments on Tuesday afternoon, hours after he met with a group of African American ministers in Springfield. Several black ministers contacted today said they found the comments inappropriate and off-the-mark, but added that they would not judge Markey solely on that comment. Markey's opponent in the Democratic primary, Representative Stephen Lynch, condemned them, as did Republicans.
In a statement today, Markey repeated his opposition to Citizens United and criticized Republicans for failing to embrace a pact to curb spending from political action committees in the senate election. But, he did not disavow his earlier remarks.
"The Supreme Court had the horrific judgment to issue the Dred Scott decision and people rose up to challenge it,'' he said. "Today, we're faced with another egregious decision that needs overturning, Citizens United. The damage the court unleashed by allowing outside money to control elections constitutes a legitimate constitutional crisis.''
Eugene F. Rivers III, director of the Ella J. Baker House and co-founder of Boston Ten Point Coalition, said Markey should sit down with African American clergy in Boston to explain "his somewhat revisionist approach to the Dred Scott case.''
"I do not understand the historiographic or historical analogy,'' he said. "That makes no sense to me.''
The Reverend Talbert W. Swan, II, president of the Springfield NAACP and one of about 15 to 20 people who met with Markey earlier Tuesday, said he agreed with Markey that there were some parallels between the two "horrible'' court decisions.
"Dred Scott basically upheld considering people as property and continuing to subjugate them and restrict their rights, while Citizens United did the opposite, by recognizing property as people and giving them rights,'' Swan said.
But, he added that politicians need to be extremely sensitive to the comparison, given the significance of slavery in American history and especially within the African American community.
"While there are some parallels, I don't think campaign finance can be compared to the subjugation of an entire people,'' Swan said.
William E. Dickerson, Jr., senior pastor at the Greater Love Tabernacle in Dorchester, said Markey probably did not intend to compare slavery with campaign finance, but people in the public eye need to be careful about their phrasing.
"We minimize the issue of the Dred Scott decision when we try to juxtapose it'' with lesser issues, he said. "In terms of its impact and significance, that should stand alone.''
None of the pastors thought the comments would irreparably damage Markey in the black community however. They said black clergy are looking for candidates who can show a long-term commitment on significant issues, including incarcerartion rates for people of color, urban violence, and education.
Swan said he expects Markey will garner support from many of the black ministers who met with him, considering his stances are in line with President Obama, Governor Deval Patrick, and others who have won their support in previous elections. But like other members of the black clergy, he said he wants to hear from all the candidates, from both political parties, before making a commitment.
"I think the day of African Americans automatically supporting the Democratic candidate are over,'' Swan said. "We have a more informed electorate that wants to weigh where the different candidates stand on the issues.''
Dickerson said someone from Lynch's campaign has already reached out to request an opportunity to address his church, and he expects other candidates from both parties to do the same. African American voters, who are overwhelmingly registered as Democrats, could be especially influential in the party's primary, and Lynch's campaign was quick to seize on Markey's comments.
"I don't think it's right to compare Citizens United to the Dred Scott decision,'' Lynch said in a statement. "Dred Scott kept an entire race of people in bondage and perpetuated the horror of slavery in America. I'm not sure there are any Supreme Court decisions that rival Dred Scott in infamy.
Lynch said he also supports constitutional amendment to overturn Citizens United.
Republicans tried to cast the comments as an example that Markey is out of touch.
"Agree or disagree with federal campaign finance law, it's ridiculous and offensive to compare it to the horror of slavery,'' said Brad Dayspring, communications director for the National Republican Senatorial Committee.
Be civil. Be kind.Read our full community guidelines.


text:
Being your basic coward, I try and talk my way out.
He wrote that on Bill's forum in another thread.
I am sure he is not a coward but he sees value in "talking_defusing" which can be a good thing.
But I was going through some scenarios in my head Saturday after having witnessed some ##### giving someone a bad time of it while this someone was trying to defuse and appease.
It was a group of young people made up of a few guys and a few girls cruising the crowded mall in Providence Rhode Island.
What happened was this someone had absentmindedly walked into the group at right angles and brushed up against one of the women.
The more he apologized and tried to defuse, the more brazen one of the punks got into his face, until he was able to walk away with his tail between his legs.
Pretty hard for me to watch that and to feel good about seeing the punk empowered by the event. All my thoughts were about "go ahead and make my day" could not accept verbal defusing in that situation.
Anyone have this problem? I mean for real not just forum talk.
[This message has been edited by Van Canna (edited September 04, 2002).]


text:
Xbox One Controller - Sidemen Edition (Special Edition)
Custom Controllers UK are happy to introduce the official Sidemen controller, also known as the Sidemen Special Edition.
The CCUK design team worked alongside the Sidemen to bring the first exclusive Sidemen controller to the fans. The team were inspired by the Sidemen's clothing range opting for a subtle white back ground with the Sidemen XIX logo in black on the right hand side of the controller, the design was finished with a black trim creating a distinct design recognised across the globe.
Custom Controllers UK is the leading manufacturer of customised gaming. The CCUK team hand crafts and customises over 500 different designs within the U.K. CCUK are specialists within the gaming sector striving for brilliance, the mission of CCUK is to change the face of gaming as we currently know it, going above and beyond the expected standard.
CCUK believes all gamers should be represented by the controller they use. Make a statement.
Experience the action like never before with the Xbox One Wireless Controller. New Impulse Triggers deliver fingertip vibration feedback, so you can feel every jolt and crash in high definition (in supported games). Redesigned thumb sticks and an all new D-pad provide greater precision. And the entire controller fits more comfortably in your hands.
- For Xbox One and Windows 7/8.1/10
- Up to 18-foot wireless range
- Compatible with Xbox One Play & Charge Kit, Chat Headset, Stereo Headset, Chatpad and more
- Includes 3.5mm stereo headset jack


text:
After careful investigations, it turned out that the ChEBI file contained a few entries which were not MDL molfiles, but queries for the ISISBase system. Those cannot be read by the CDK MDLV2000Reader. However, it crashed on it, instead of failing more savely. That's not nice, and fixed. But, the problem is rather recurrent, and the reason why I like CML so much: invalid input. CML, based on XML, has several general validation approaches that give in-depth error messages of what is wrong with the file.
So, I asked on the BOx what the Open Source cheminformatics community had to offer for this. Turns out that several tools find problems in the files, but none could report where the error occurred.
Now, some time ago, I played with two reading modes, RELAXED and STRICT, as faulty files is core cheminformatics material, and the software is blamed if the QSAR model resulting from it is not good (seriously). Anyways, a small API change in the CDK would make a validating MDLV2000Reader quite a step closer, but I had not followed up on it until last Friday where I patch I was reviewing caused 6 new unit test fails. The new fails were caused by a assumption which turned out the be false in the test files used in those 6 unit tests.
The MDL (or Symyx) molfile specifications (not an Open Specification) defines an atom block line as:
xxxxx.xxxxyyyyy.yyyyzzzzz.zzzz aaaddcccssshhhbbbvvvHHHrrriiimmmnnneeebut does not specify which fields are optional. And indeed, many tools around save MDL molfiles with one or more fields missing, leading to shorter than expected line lengths. And, as you might have expected, the failing unit tests had files with lines missing the field introduced by the patch, causing Exceptions being thrown around. I have yet to make up my mind of the lack of those fields is a problem in the file, or allowed by the format. In either case, the information from that field is not available, and the reader could safely ignore the missing information. Per user demand.
Now, personally, I rather send the file back to the user with a proper error report and show them what is wrong with the file. Or better, provide them with a MDL V2000 text editor (e.g. in Bioclipse) which would graphically highlight errors, as many of us are used to with Eclipse:
CDK Patch
So, I am hacking up a patch for CDK master to allow error reporting by IChemObjectReaders. The initial version of the API update and use in the MDLV2000Reader are available as Gist 290659. They are not final yet, as I realized when making the above screenshot, that merely int col is not enough, and that I actually need the startCol and endCol positions instead. Also, there are only an error level at this moment, and no warning level as in the screenshot.
That said, I created a jar (ant dist-large) and saved it as mdlCheck.jar, and wrote a bit of Groovy:
which defines a class implementing the new IChemObjectReaderErrorHandler and then reads a MDL molfile. And the output looks like it fulfills my needs:
$ CLASSPATH=mdlCheck.jar groovy mdlCheck.groovy src/test/data/mdl/test6.sdf location: 5, 35: Could not parse mass difference field. -> For input string: "" location: 6, 35: Could not parse mass difference field. -> For input string: ""Note to myself, that atom block does not like like a MDL molfile atom block at all! Every second line outputs the Exception passed to the error handler. I have to say, those messages are rather cryptic, but resulting from a NumberFormatException, if not mistaken.
Or, another common found issue (using D and T as element symbols):
$ CLASSPATH=mdlCheck.jar groovy mdlCheck.groovy src/test/data/mdl/hisotopes.mol location: 6, 32: Invalid element type. Must be an existing element, or one in: A, Q, L, LP, *. location: 7, 32: Invalid element type. Must be an existing element, or one in: A, Q, L, LP, *.
Enough for now... dinner time.


text:
While most of us have Christmas on our minds, Universal Studios Hollywood is already planning for next Halloween.
> Halloween Horror Nights 2011: Review | Photos | Celebrities
Universal has been conducting an online survey to gauge fan interest in 50 movie and television properties as potential haunted maze themes for Halloween Horror Nights 2012.
The annual post-Halloween poll offers fans a glimpse into what could be on the horror horizon at Universal.
During the past few years, the revamped Horror Nights has presented mazes based on some of the biggest horror properties: "Friday the 13th," "A Nightmare on Elm Street," "Texas Chainsaw Massacre," "Halloween," "Scream" and "Saw."
Among the possibilities for 2012 and beyond: "Psycho," "Amityville Horror," "Aliens," "Poltergeist," "Paranormal Activity,""28 Days Later," "American Werewolf in London," "Freddy vs. Jason," "The Shining," "Hellraiser," "True Blood," "Dexter" and "American Horror Story."
This year, Universal worked directly with big-name talent to bring many of the mazes to life: Alice Cooper ("Welcome to My Nightmare"), Eli Roth ("Hostel") and Rob Zombie ("House of 1000 Corpses").
As a result, this year's online poll also included musicians Marilyn Manson, Lady Gaga, Ozzy Osbourne, Kiss and Slipknot and filmmakers John Carpenter, Clive Barker, Wes Craven, Tim Burton and Quentin Tarantino as potential maze-making partners.
Via Twitter, Horror Nights creative director John Murdy has put a few movie maze contenders on his short list ("Trick 'r Treat" and "Evil Dead") while declaring some other titles difficult to acquire ("The Exorcist" and "Dawn of the Dead") or hard to adapt "Zombieland" and "Silent Hill").
Among the movie titles in the online poll with planned 2012 remakes: "Halloween 3D," "Texas Chainsaw Massacre 3D" and "Resident Evil: Retribution." "The Lords of Salem," a 2012 thriller about witches written and directed by Rob Zombie, is the only unreleased movie on the list.
- Amusement and Theme Parks
- Halloween
- Politics and Government
- Elections
- Halloween Horror Nights
- Movies
- Entertainment
- Unrest, Conflicts and War
- Rob Zombie
- Paranormal Activity (movie)
- 28 Days Later (movie)
- Zombieland
- Aliens (movie)
- Psycho (movie)
- The Shining (movie)
- Eli Roth
- Clive Barker
- Tim Burton
- John Carpenter
- Alice Cooper


text:
In the past 18 months, I've probably entered Tahrir Square more than 100 times, and I like to think I've developed pretty good instincts about the place. Normally when I think things are going to be dangerous there–with clashes between protesters and the police or among different sets of protesters–I can see it coming and I come equipped.
Over time, I've developed my Tahrir battle kit: extra tight hiking boots just in case I need to run, no wallet–just my Egyptian national ID, a small reporters notebook that slips into my back pocket, a bandana and a small bottle of vinegar to deal with teargas exposure. I travel light and inconspicuous; I keep moving and don't draw a crowd. A modified version of these guidelines kept me relatively safe for two years of reporting in Iraq as well.
The week before last, Tahrir witnessed violent rock-throwing clashes between secularist revolutionary groups opposing President Mohamed Morsy and supporters of Morsy's Muslim Brotherhood. The previous month saw the area engulfed in battles between rock-throwing youth and riot police as tear gas volleys arced into the square.
But last Friday was supposed to be different. The secular Morsy opponents were going to come out in force again, but the Brotherhood–either due to the bad press they had received from the previous week or because they were distracted by their internal party elections that day–had pledged to stay away from Tahrir.
(MORE: Has Egypt's Muslim Brotherhood Staged a Coup Against the Military?)
The primary challenges, I thought, would be estimating crowd size and observing group dynamics among the varying factions. My expectations of the day were peaceful enough that I felt fine carrying my laptop into the square and planning to write a dispatch for TIME that evening from a local coffee shop. I even brought my wife with me for a brief tour of the square, something I would never do if there was the tiniest whiff of instability.
The last thing I expected that day was to end up in the middle of a chaotic mob scene.
One of my side-gigs (in addition to writing for TIME) is doing reports for France 24's English Language channel. That night, I had done one standup live-shot at 7 p.m.–as usual splitting a camera position with my French language colleague Sonia Dridi. We had long since developed a practiced rhythm on this. One of us would be chosen to speak first, then the other would quickly switch in with microphone and earpiece to do their live-shot. The whole thing was usually over within six minutes.
Unlike most Tahrir protest Fridays, the local video production company had made a decision to set up their camera position at street level instead of the usual balcony overlooking the square.
But already, even in an earlier live-shot that day, crowd control had been a problem. Large groups of curious onlookers had gathered around the camera setup and made it difficult to hear the news anchor from Paris. It was annoying but merely that; it never felt like a threat.
I wandered the square for a bit more, camped out at coffee shop to write my dispatch and was halfway done when it came time to do a second live-shot at 10:30. So I packed up my computer bag and went to join Sonia.
It is often the tiniest details that set disasters in motion. In retrospect, one of the crucial contributing factors (in addition to the decision to broadcast from street-level) was simply that Sonia's live-shot came first. That meant by the time I arrived at the broadcast position, she was already standing under the bright TV lights and drawing a crowd. That broke two of guidelines I had set for myself: we were static and we were conspicuous.
(PHOTOS: Mohamed Morsy Declared Egypt's First Islamist President)
Another tiny but crucial contributing factor was the car bombing in Lebanon earlier that day. Understandably, this topped the news and pushed our report further into the evening–which meant Sonia really had to stand under the lights. By the time she started her French-language report, we were hemmed in on all sides and the crowd was starting to act obnoxious. I was one foot away from Sonia, carrying both of our bags and pleading with them to let her work without distraction. The mood wasn't angry or malevolent–just rowdy. I remember that standing right next to me was a veiled Egyptian mother in her 30s holding the hand of a boy who looked about three years old and was carrying a toy pistol.
As Sonia spoke, several good Samaritans in the crowd linked arms with me and each other to give Sonia some breathing room. A young production company employee named Ali was also there trying to calm things down.
By the time my instincts started to kick in that I didn't like the way things were going, it was far too late. Just before Sonia was supposed to start speaking, I leaned in and told her not to wait around for me to finish my live-shot. She was to take both our bags and head straight to the nearby Hardees fast food restaurant. When she finished I handed her the bags and told Ali, "Take Sonia straight to the Hardees. Take her personally right now."
That's when everything flipped. The crowd surged in with Sonia at the center. I dropped my microphone and grabbed her in a face-to-face bear hug for protection.
It was as if everyone had suddenly gone insane. We were at the center of a storm of bodies as I held on to Sonia and physically pushed through the crowds. She was understandably scared and crying a little and the only thing I could tell her was to keep breathing, keep looking at me and everything would be all right.
We moved in a lurching sort of crab-walk at the center of the maelstrom. Bodies and anonymous hands were pressing in from all sides. Several of the men were absolutely trying to molest Sonia and remove her clothes. However, even now, in retrospect, she is reluctant to characterize what happened as a "sexual assault" and I agree with her.
Still, it was definitely mass harassment and definitely dangerous. But it was almost more of a kind of hysteria, a "madness of crowds" situation than a coordinated sexual attack such as happened to CBS correspondent Lara Logan in Tahrir on the day Hosni Mubarak resigned. I do believe, however, that something along those lines might have happened to Sonia if I'd lost her in the crowd. This was a group of hyper, borderline-feral men — both gropers and thieves taking advantage of the chaos.
(MORE: Cairo's Many Shades of Protests: What They Reveal About How the New Egypt Operates)
In a moment of dark comedy that we would laugh about later, my jeans at one point fell down around my ankles and I struggled to pull them up with one hand while keeping my hold on Sonia. The priority was to keep her on her feet and make sure I never lost my grip.
It was honestly hard to tell in several cases just who was trying to grope Sonia and who was trying to help us. But there were at least five young guys in the crowd who actively helped me protect Sonia–and without them we never would have made into the Hardees.
Depressingly, the employees at the fast food restaurant had obviously had some practice giving emergency shelter to women fleeing rowdy Tahrir mobs. They reacted immediately, pulling down the metal gate. For a while we were trapped in there as Sonia struggled to compose herself and we waited for the mob to disperse. She was traumatized and angry but not physically hurt. We both knew it could have been a lot worse. At one point I slipped out and made a hopeless attempt to find our bags, but of course they were long gone. Finally I hailed a cab and asked the driver to wait at the curb. The crowds outside had thinned and we made a quick getaway into the cab, but the sight of Sonia set off a roar and a couple young hooligans started pounding on the hood as the driver made a fast getaway.
The most amazingly thing about the whole experience was how quickly it took place. Sonia probably finished her stand-up at around 10:40. When we made it into the taxi and left Tahrir, we were stunned by the dashboard clock: it was 11:07. The entire pre-Hardees mob scene must have taken about 5 minutes.
I probably shouldn't be shocked by what happened to Sonia and me but naively I suppose I still am. Sexual harassment and incidents like this are one of the modern plagues of Egypt. It's not an Arab thing or a Muslim thing; it's a very specific Egyptian thing that has been building for years and it could take decades to unravel. There's a common misconception that the revolution unleashed this sort of behavior in Egyptian men, but that's simply not true. It happened under Mubarak as well; in one notorious case, a gang of wild youth rampaged through downtown on a holiday weekend targeting any woman they saw. And that's not even mentioning the kind of everyday predatory sleaziness that women–both foreign and Egyptian–have to fend off everyday. But Tahrir has become the focal point for this new spike in mob attacks on women partially because that is where the crowds and the foreign journalists converge. Months of back-and-forth political upheaval have turned it into some sort of consequence-free zone in many men's minds.
(MORE: Egypt's Young Revolutionaries Have Lost Their Way)
Several months ago, I interviewed Heba Morayef of Human Rights Watch's Egypt office on why this was going on in Tahrir Square. She said that everyday harassment was a long-time issue but these mob assaults were a disturbing new trend. "The attackers know they're unlikely to be prosecuted because sexual harassment is not taken seriously," by society or the authorities, " Morayef told me. "And they know that Tahrir is a space where military and police do not want to enter."
These sort of Tahrir mob scenes have happened so frequently that the phenomenon has taken on a horrible business-as-usual familiarity. The Hardees employees told me that this was hardly the first time a terrified woman had sought shelter from the mob there. I'll confess that when Natasha Smith, a young British woman, was attacked in June, it barely registered with me.
I love Tahrir Square. I'm genuinely nostalgic for the way that place felt during the revolution. In the book I wrote about the Egyptian revolution, I spoke of Tahrir like it was a living character just as vital and dynamic as any of the revolutionaries I interviewed.
Here's an example from the prologue: "Immediately Tahrir became the epicenter of a revolution. Protestors not only transformed it, they were themselves transformed by their presence in it. Tahrir became a revolutionary organism unto itself, bigger than any one citizen or political faction–and most important, bigger than (Hosni) Mubarak and his government."
Now I'm walking around angry. I don't know if I'll ever feel the same way about Tahrir Square again. That place meant something powerful and inspirational; for a brief window it embodied the best of the beleaguered Egyptian spirit. Tahrir was the heart of the external revolution against Mubarak's government, but there's an internal revolution in public behavior and social decency that desperately needs to happen and that still hasn't even started.
I feel like over the past 18 months, on multiple levels, we have let Tahrir Square down.
Ashraf Khalil is a Cairo-based journalist and author of Liberation Square: Inside the Egyptian Revolution and the Rebirth of a Nation


text:
From 0 to hero
Battle the apocalypse
Welcome to the enthralling world of Orience, where a turbulent war of nations threatens to tear the land apart. Rendered in rich and vivid High Definition for PlayStation 4, prepare for an adventure of gritty emotional storytelling and high stakes battles.
Choose from 14 playable warriors, each with distinctive weapons, abilities and combat styles – and take the fate of the world and its four crystals on your shoulders.
Step into the fray as Class Zero, a group of students from an elite military academy whose country is attacked by an aggressive neighbouring Empire. In the brutal and harrowing struggle that follows, you must engage a range of powerful magical and combat abilities using a new and exciting battle system, to defeat the Empire and uncover the secrets behind the war.


text:
The House on Friday passed a bill to make permanent the individual and small business tax cuts that had been set to expire after 2025 as part of the overhaul enacted late last year.
The bill, passed by a 220-191 vote, was the final piece of a three-bill package the Republicans labeled Tax Reform 2.0. The first two pieces, providing additional incentives for Americans to boost retirement savings and more tax breaks for startup businesses, were passed on Thursday.
The bill approved on Friday would extend the lower individual tax rates enacted last year as well as the larger standard deduction and child tax credit, a 20 percent deduction for pass-through income and a doubling of the estate-tax exemption. It also would lock in limits on the deductibility of state and local taxes.
Unlike last year's tax law, some Democrats supported the two bills passed on Thursday, and three — Reps. Conor Lamb of Pennsylvania, Jacky Rosen of Nevada and Kyrsten Sinema of Arizona — joined nearly all Republicans on Friday in voting for the extension of the cuts. Sinema and Rosen are both running for Senate. Other Democrats, opposed to the legislation, warned that Republicans would use the deficit-increasing effects of their tax law as an excuse to cut Medicare and Social Security benefits in the future.
Ten Republicans from high-tax states voted against the extension because of the cap on state-and-local deductions.
The second round of tax cuts would cost $631 billion through 2028, according to Congress' nonpartisan Joint Committee on Taxation, or $545 billion once economic feedback effects are factored in — and trillions more after that. The JCT analysis also found that, while making the tax cuts permanent would provide a modest boost to the economy after 2025, it would slow economic growth over the longer term.
Why it matters: The Senate has no plans to vote on the Tax Reform 2.0 package, meaning that the House votes are mostly about pre-election messaging — and after the tax bill was passed Friday, House Republicans canceled October votes and went into recess until November 13, allowing candidates more time to campaign. Election season is in full swing now. Still, Democratic support for the retirement savings and startup bills suggest that there's room for lawmakers to advance those pieces of legislation in the future. "We've always looked at it as part of a longer game," Brad Close, senior vice president of public policy and advocacy for the National Federation of Independent Business, told Politico. "Let's see where the lame duck goes. I think a lot of it depends on how the election goes."


text:
Dell has scaled back the range of consumer PCs with processors from Advanced Micro Devices that it sells on its website, focusing almost exclusively on systems with Intel processors.
Dell's entire line of AMD-based laptops for consumers, as well as most of its AMD-based consumer desktops, will now be sold only through Dell's 10,000 retail outlets worldwide, Dell spokeswoman, Anne Camden, said.
Except for one desktop, the Inspiron 531, which includes the AMD Athlon 64 X2 Dual-Core 4000+ processor, Dell will focus its online consumer sales on Intel-based PCs. For businesses, Dell will continue to sell a range of AMD-based systems online.
The decision, made this week, could be a setback for AMD. The Intel rival received a big boost in 2006 when Dell began offering its chips in desktops, laptops and servers.
AMD-based systems tend to be priced lower than Intel-based systems, so it makes sense for Dell to ship AMD products through retail channels, said Dean McCarron, founder and principal at Mercury Research.
"[Dell's decision] is not that surprising given that AMD's primary strength is the consumer retail channel," he said. Price points on PCs tend to be lower in the retail market, and retail buyers are more sensitive to cost than online buyers, McCarron said.
AMD said the move was part of a strategy to offer a wider range of AMD-based PCs through retail channels. "We are always evaluating product offerings and how customers can access them," Camden said.
Not many consumers buy systems based on the processor type, she said, and few distinguish between AMD and Intel processors. Users select PCs based mostly on price and what they will use them for, such as surfing the Web or playing music and videos, she said.
Dell has expanded its in-store offerings over the past six months by signing up more retailers, including Best Buy and Wal-Mart in the US, Tesco in the U.K. and Bic Camera in Japan.
The retail strategy helped the company expand its lead over Hewlett-Packard as the largest US PC vendor in the fourth quarter of 2007, according to IDC. However, HP remained the world's largest PC dealer, topping Dell, Acer and Lenovo, IDC said.
Hewlett-Packard already offers more AMD-based PCs in retail than online, so Dell's decision isn't a first, McCarron said. Until it won over top-tier PC vendors several years ago, AMD relied on the retail market and white-box vendors for its chip sales.
The effect of Dell's strategy shift on AMD remains to be seen, McCarron said. It is a large and important PC vendor, but it is also a relatively new partner for AMD.
AMD has suffered some setbacks recently, reporting five straight quarterly losses and delaying shipments of some new desktop and server processors. Its market share was 23 per cent in the fourth quarter of 2007, down a fraction from the year before, while Intel's market share climbed slightly to 77 per cent, according to IDC.


text:
Who Are We?
The Anatomy of a Knitter, As Revealed in the Knitter's Review Polls
What happens when you take more than 200 questions and look at the answers?
We knitters may differ in many ways, but we share a peculiar and unspoken Your mother taught you how to knit. Or did you teach yourself? Interestingly enough, it was a tie. Although legend usually dictates that the grandmother passes on the craft to her grandchildren, only 15% of you learned from your grandmother—the same percentage as learned from a friend or teacher.
But you've been knitting a long, long time, having learned at the age of 10 or younger (43%). Several of you are also lapsed knitters (19%), recently returning to the fold after years of silent needles. And a sprightly 14% are new recruits, having learned to knit less than a year ago. Welcome to the family!
You feel absolutely passionate about knitting (41%). Although you consider yourself an intermediate-skilled knitter (47%), you still have lots to learn (72%).
In the Beginning
the first scarf I made from my handspun yarn, using a simple K1/P1 ribYour first project was a scarf (33%) or, for the more ambitious, a sweater (22%). You chose a different yarn than the one specified in the pattern (48%), and you worked with the yarn in your right hand (52%).
But soon you got distracted by all the beautiful yarns and patterns out there, and you started another project without having finished this one (82%). You felt guilty about that unfinished project (46%), but then again, you do tend to get bored with your projects (52%).
The Merits of Multitasking
Still, you show remarkable restraint. You usually have no more than 10 projects in various states of completion (80%), although some of you stopped counting your unfinished projects years ago (16%).
While your oldest unfinished project tends to be just a few years old (30%), some of you have projects so old they require carbon dating (30%). If the project stops being fun, however, you're not afraid to abandon it completely (41%).
Stocking Your Stash
inside the Woolly Lamb in Pennington, New JerseyWhen it comes time to find yarn for your next knitting adventure, you tend to visit your local yarn store (59%) despite the fact that you feel perfectly comfortable buying yarn online (51%). If it's a new store, you may feel a bit nervous entering it for the first time (43%), although enthusiasm and curiosity usually win out (36%).
In your quest for a new project, you tend to fall in love with a pattern (51%) and then find a yarn to go with it—preferably wool (81%).
Your budget? For an adult-sized sweater, you'll spend anywhere from $60 to $120 (54%), although the more frugal manage to fund an entire sweater for $60 or less (32%).
If you really like the yarn, you'll usually buy it regardless of the cost, figuring that it's worth the extra money in the long run (48%).
You do feel a little self-conscious about your yarn stash at times (37%), which is large but always in need of more stocking (84%). (When storage space gets tight, you get creative.)
Picking Your Needles
choices, choicesWhich needles do you use? Well, that depends on the project, yarn, and your mood (32%). Generally you prefer bamboo (26%) and metal (25%) needles. Whenever possible, you like to use circular needles (56%).
Watch Your Swatch!
Two swatches of the Jade Sapphire bulky cashmere
Before delving into the project, you begin by knitting a test swatch (40%). Well… sometimes. You often get so impatient to begin that you jump right in, using your first few rows as a gauge swatch (34%).
Goof Tolerance
So your gauge is set, you begin your project. Things are going well until you look down at your work and discover something terribly wrong. What do you do?
Most of you will try to figure out how you can fix it without undoing your work (49%). But what if you discover another mistake later on?
Heck, a few modest goofs don't count (66%), unless you're one of those people with zero tolerance for any mistakes (28%)—in which case the entire project must be unraveled and started from scratch (30%).
Are You a Blocker?
So you've finished your project. Will you bother to block it? While some of you insist on blocking (31%), others never bother with this step (38%).
Knitting for Others
don't try this at home!Who is this sweater for, anyway? If one thing is clear, it's that you're a generous bunch. Last December you knit many gifts for friends and family (48%), including several bulky scarves (54%). The gifts were very well received (68%), although in a few cases you thought the recipients were slightly disappointed (26%).
Generally you're surrounded by extremely supportive friends and family (48%), although they may occasionally shoot you an exasperated glance (41%).
Gifts from Others?
Despite those supportive friends and family members, you're clearly long overdue for your own knitted gifts. Nobody has knit you anything in a long, long time (53%).
And in some cases, you've never received a handknit gift (35%). Sounds like it's time to befriend more knitters!
But you remain cautious about knitting for a new love interest (41%) for fear you'll be hit by the curse of the love sweater. While others maintain it's just a silly superstition (30%), some of you have experienced the curse firsthand (15%).
It doesn't hurt to be careful.
Turning Passion into Profession
Annie Modesitt has made a career out of knitting – here she teaches at the 2004 Knitter's Review RetreatIf knitters were given a toaster oven for every dozen new recruits, we'd have a lot of appliances on our hands. That's because the majority of you enjoy teaching others how to knit whenever the opportunity presents itself (55%), and some of you (10%) even get paid to teach professionally.
In fact many of you dream of a career in the fiber arts—you just can't figure out how you'd go about getting started (37%).
You dream of owning a yarn store, but doubt you'd have the courage to do it (58%). Some of you actually do have a career in the fiber arts (6%), while a few others (9%) have your plan for success all figured out.
What's Next?
You made ambitious lists of projects for 2005. Although many of you don't believe in making official New Year's resolutions (38%), some of you did (28%).
a felt swatch in the snowWhile some of you are curious about learning how to dye your own yarn (37%), a larger majority has no interest in this whatsoever (38%). Felting is on some people's to-try list (27%), although most of you (47%) have already tried felting and enjoy it.
While many of you (59%) are tempted to try using software to design your next project, most of you (50%) have no interest in learning about knitting boards.
Question Assumptions
If this exercise has taught me anything, it's that you can't make assumptions about knitters. For every person whose answer was in the majority, several more people answered the polar opposite—but because my polls often include several contrary answers, they remained a statistical minority.
For example, 43% of you agreed that all knitters love cats, but 34% of you insisted that such an assumption is absurd.
Then again, you categorically chose yarn over both chocolate (77%) and caffeine (66%).


text:
Story highlights
NEW: Search is called off for crew members missing after a ship collision Wednesday evening
NEW: Passing ships have been told to be on the lookout, Netherlands Coast Guard says
Thirteen people are rescued; seven are missing
The Baltic Ace began sinking immediately after the collision
The search for the missing crew members from a North Sea cargo ship collision has been called off Thursday afternoon, the Netherlands Coast Guard said in a statement.
The search will not be resuming and passing ships have been told to be on the lookout, the Netherlands Coast Guard said.
At least four people are dead and seven others missing after a container vessel collided with a car carrier Wednesday evening, the Netherlands Coast Guard said.
The carrier Baltic Ace began sinking immediately after it collided with the container vessel in a busy shipping lane, about 60 kilometers (32 miles) west of Rotterdam, according to Coast Guard spokesman Peter Verburg.
Thirteen crew members were rescued and taken to hospitals in Rotterdam and at the Koksijde Air Base near Ostend, Belgium.
Those rescued were suffering from hypothermia and minor injuries, the spokesman said.
The nationality of the crew was not immediately known.
The Baltic Ace had been en route from Zeebrugge, Belgium, to Kotka, Finland; the container vessel was en route from Grangemouth, Britain, to Antwerp, Belgium.


text:
Travel Agency Mornar exists in Montenegro since 1991. The secret to continuous improvement lies in the twenty three years of tradition and experience, and professional team of ten employees who are at your disposal. The Agency cooprate with large tour operators in both hotel and private accommodation. We are able to organize seminars, business meetings and various team-building.
Year after year we worked with many tour operators from different countries: England, Germany, Russia, Italy, Ukraine, Czech Republic, Hungary, Romania, Belarus, Croatia ...
A large number of foreign tour operators are the right recommendations for future business associates for quality of service and cooperation.
Due to numerous requests of foreign partners we have expanded our operations by opening offices in Belgrade (01.03.2008.) We can offer a variety of winter holidays, vacations, cruises, educational programs,visits of european cities, as well as bringing international visitors to Belgrade and Serbia. We also take part in organising individual travels through Serbia
(monastery tours, village, mountain, spa, recreation, tourism manifestation, ...).
In Mornar you can make reservations for rent-a-car, pay the travel and health insurance..
We will try and continue at any time to provide the highest quality professional service, because we are here for you. A large number of satisfied customers and partners is our best recommendation!!!
Mornar Travel Montenegro
Petrovac na moru
e: firstname.lastname@example.com
t: +382 33 461 410
f: +382 33 461 455
- Book & Save up to 100€
- No booking fees
- Money back guarantee
- Thousands of satisfied clients
- Pay upon arrival


text:
Francis recalled, giving Rockies 13 pitchers
NEW YORK -- Having placed Carlos Gonzalez on the 15-day disabled list, the Rockies on Wednesday recalled left-hander Jeff Francis from Triple-A Colorado Springs to fill the open roster spot.
Colorado manager Walt Weiss said Francis, 32, gives the Rockies a much-needed arm out of the bullpen. With the Rockies this season, Francis was 2-5 with a 6.63 ERA in 12 games, 11 of which were starts.
"We've been a little shorthanded," Weiss said. "But going back home, Jeff bumps us back up to 13 pitchers. It'll be good to see him in that role."
Francis has had two stints in Triple-A this season, going 2-2 with a 4.34 ERA in 11 games -- including six starts.
The Rockies first sent Francis down on June 20, then recalled him on July 28. But he was optioned to Colorado Springs again on Aug. 1 to make room on the roster for pitcher Chad Bettis.
Now he's back because the Rockies were in need of another reliever. Weiss said Edgmer Escalona, who dealt with a sore left calf after being hit with a line drive Thursday in Atlanta, was sick and couldn't pitch.
"The previous days he was dealing with that comebacker," Weiss said. "But yesterday he was sick. He was sick on the off-day and then yesterday. He wasn't even here, he didn't come to the park."
Wilton Lopez had to pitch two innings in Tuesday's 3-2 loss to the Mets.


text:
Waterman, Jill is the author of 'Helping at Risk Students: A Group Counselling Approach for Grades 6-9', published 2008 under ISBN 9781606230022 and ISBN 1606230026.[read more]
You can find lots of answers to common customer questions in our FAQs
View a detailed breakdown of our shipping prices
Learn about our return policy
Still need help? Feel free to contact us
View college textbooks by subject
and top textbooks for college
With our dedicated customer support team, you can rest easy knowing that we're doing everything we can to save you time, money, and stress.


text:
The voice of Will Oldham on those earliest Palace releases has an equivalent sonic organicity, like piles of vegetable matter rotting on a compost heap. There is initially something disturbing in its feral rawness - it seems to allow us an unsettling glimpse of the eternality, the permanence, of things beyond their mundane (in a literal sense) appearance. It embodies a certain humanity, distinct from modern, moralistic reading of that word; a humanity beyond questions of good and evil, aware that both of these states contribute to the essence of an existence in thrall of nature.
You'll also like Palace Brothers and Palace Songs. This artist is a new name for Bonnie 'Prince' Billy.


text:
Our Story"We hand-fabricate our jewelry the old fashioned way. A photo of a custom designed ring that we finished making on our work bench. Our ...
Curbside Pickup, Free Shipping, In Store Appointments for Services and PurchasesDeleuse New and Vintage Jewelry, Accessories, Outerwear, Home Collections, Deleuse Natural Skin Care Located in the San Francisco Bay Area in Fai...
Deleuse Skin Care Routine on VideoWatch the video demonstrating how to use: Deleuse Cleanser Toner Mist Algae Mask Honey Mask Restorative Facial Cream ...
The Robb Report: Famous Necklace by Suzanne Belperron at AuctionCourtesy of Sotheby's This 1940s Diamond-and-...
Victoria Gomelsky for the NYT "Shopping for a Diamond Is About to Change""A decent quality two-carat Argyle tender stone probably starts at $1 million a carat, wholesale, and goes up," Mr. West said. "But when you have...
Getting Engaged?It's always the time for love. There are many choices; vintage jewelry, diamond bands, gemstone rings or create a ring that is uniquely yours. Enga...
Pascal LacroixRaised in the South of France by artist parents in the splendor of the "Gorge du Verdon" Provence region was the perfect cruc...
SOLD! For 26.6 Million Dollars!October 12, 2020. The Robb Report This Massive Purple-Pink Diamond Is Expected to Fetch $23 Million at Sotheby's The 14.83-carat "Spirit of the Ros...
"Janet, thank-you for everything you do. As I said before, you are truly an artist, and that is why it is so special buying jewelry from you." Peter, Atlanta, GA
" Beauty, exquisite design, pleasant and personalized attention. These qualities have been constant in our 20 years of shopping with Janet and Jeff Deleuse – Two exceptionally talented and caring people. The Best!' Helen P.,Belvedere
"This store has a very pleasant environment and Jeff and Janet are both kind, wonderful people. I used Jeff a few times for appraisals and he was very thorough and was happy to answer lots of questions. He uses scientific methods and tests rather than going solely by appearance as some jewelers will try to do, and his expertise is well respected. On one occasion, he even went out of his way to help expedite a deal for me. He has my highest recommendation. Suzanne T., San Rafael, CA
"Jeff is an incredible gemologist who knows everything there is to know about gem stones. He is a true professional and can be trusted. The quality of their work is impeccible and always consistent. I would recommend Deleuse Jewelers to anyone looking for a new, "bauble," for themselves or someone special!" Terri B., Ross
"I have used Deleuse Jewelers for many years - for everything from purchasing jewelry to repairing jewelry to getting appraisals on jewelry. Their service and work is superb. I highly recommend them." Suzanne S., Tiburon, CA
"I purchased this beautiful chain from Janet Deleuse about 3 weeks ago. It was an online purchase so I was hoping I would be pleased. It exceeded my expectations as it was exactly as pictured. Delicate and perfectly crafted. Packing was very secure and shipping was quick. I would not hesitate to purchase from Deleuse again! Michele, New Jersey
"Janet and Jeff designed and crafted our wedding rings and did a great job. They worked with existing diamonds we had in an antique ruby cocktail ring, added the sapphire stone and made a beautiful pendant with the ruby. In addition, they designed earrings for our daughters. All are still in great shape today. They are easy to work with and very reliable and trustworthy." Peg M., San Anselmo
Accreditation includes diplomas from the Gemological Institute of America and the American Gem Society and thirty years of experience.
Featured collection
All gold jewelry is fine quality 14k, 18k or 22k. Made in Italy, Germany and the USA.Gold →


text:
Can I Do Owner Financing In Houston If I Have A Mortgage On The Property?
Do you have a house to sell? Perhaps you're thinking about selling, and maybe you're thinking about seller financing. But if you have a mortgage on your house, you might be wondering, "Can I do owner financing in TX if i have a mortgage on the property?" We get this question a lot so we … Continued


text:
or browse all recipes »
get my FREE weeknight meals e-book!
Please try using the search form below:
Hi, I'm Katie and this is my Vermont kitchen. I'm a classically trained chef, former food stylist and also a reformed dieter.
More About Me »
It includes 15 of my family's favorites -- recipes and meals we go back to over and over again -- including simple to follow instructions and easy to find ingredients.
I will also send you some quick tips for creating super basic but delicious and kid-tested meals!